

LIR-7 Polyclonal Antibody

Catalog # AP73649

Specification

LIR-7 Polyclonal Antibody - Product Information

Application WB, IHC-P
Primary Accession Q8N149
Reactivity Human
Host Rabbit
Clonality Polyclonal

LIR-7 Polyclonal Antibody - Additional Information

Gene ID 11027

Other Names

LILRA2; ILT1; LIR7; Leukocyte immunoglobulin-like receptor subfamily A member 2; CD85 antigen-like family member H; Immunoglobulin-like transcript 1; ILT-1; Leukocyte immunoglobulin-like receptor 7; LIR-7; CD85h

Dilution

WB~~Western Blot: 1/500 - 1/2000. IHC-p: 1/100-1/300. ELISA: 1/20000. Not yet tested in other applications. IHC-P~ \sim N/A

Format

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.

Storage Conditions

-20°C

LIR-7 Polyclonal Antibody - Protein Information

Name LILRA2

Synonyms ILT1, LIR7

Function

Part of the innate immune responses against microbial infection (PubMed: 12529506, PubMed:27572839). Specifically recognizes a set of N-terminally truncated immunoglobulins that are produced via cleavage by proteases from a range of pathogenic bacteria and fungi, including L.pneumophila, M.hyorhinis, S.pneumoniae, S.aureus and C.albicans (PubMed:27572839). Recognizes epitopes that are in part in the variable region of the immunoglobulin light chains, but requires also the constant region for signaling (PubMed:27572839). Binds to a



subset of cleaved IgM, IgG3 and IgG4 molecules, but does not bind cleaved IgA1 (PubMed:27572839). Binding of N-terminally truncated immunoglobulins mediates activation of neutrophils (PubMed:27572839). In monocytes, activation leads to the release of CSF2, CF3, IL6, CXCL8 and CCL3 and down-regulates responses to bacterial lipopolysaccharide (LPS), possibly via down-regulation of TLR4 expression and reduced signaling via TLR4 (PubMed:22479404). In eosinophils, activation by ligand binding leads to the release of RNASE2, IL4 and leukotriene C4 (PubMed:12529506). Does not bind class I MHC antigens (PubMed:19230061/a>).

Cellular Location

Cell membrane; Single-pass type I membrane protein

Tissue Location


Detected on the surface of all peripheral blood monocytes, neutrophils, basophils and eosinophils (at protein level) (PubMed:12529506, PubMed:22479404). Expression levels are very low or not detectable on monocytes, T-cells, B-cells, dendritic cells and natural killer (NK) cells (PubMed:9548455)

LIR-7 Polyclonal Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

LIR-7 Polyclonal Antibody - Images




Western Blot analysis of HepG2 cells using LIR-7 Polyclonal Antibody.. Secondary antibody was diluted at 1:20000







Immunohistochemical analysis of paraffin-embedded human-lung, antibody was diluted at 1:100



 $Immun ohistochemical\ analysis\ of\ paraffin-embedded\ human-lung,\ antibody\ was\ diluted\ at\ 1:100$




Immunohistochemical analysis of paraffin-embedded human-pancreas, antibody was diluted at 1:100







Immunohistochemical analysis of paraffin-embedded human-pancreas, antibody was diluted at 1:100



Western Blot analysis of HepG2 cells using LIR-7 Polyclonal Antibody.. Secondary antibody was diluted at 1:20000




Immunohistochemical analysis of paraffin-embedded human-lung, antibody was diluted at 1:100




Immunohistochemical analysis of paraffin-embedded human-lung, antibody was diluted at 1:100





Immunohistochemical analysis of paraffin-embedded human-pancreas, antibody was diluted at 1:100



Immunohistochemical analysis of paraffin-embedded human-pancreas, antibody was diluted at 1:100

LIR-7 Polyclonal Antibody - Background

Part of the innate immune responses against microbial infection (PubMed:12529506, PubMed:27572839). Specifically recognizes a set of N-terminally truncated immunoglobulins that are produced via cleavage by proteases from a range of pathogenic bacteria and fungi, including L.pneumophila, M.hyorhinis, S.pneumoniae, S.aureus and C.albicans (PubMed:27572839). Recognizes epitopes that are in part in the variable region of the immunoglobulin light chains, but requires also the constant region for signaling (PubMed:27572839). Binds to a subset of cleaved IgM, IgG3 and IgG4 molecules, but does not bind cleaved IgA1 (PubMed:27572839). Binding of N-terminally truncated immunoglobulins mediates activation of neutrophils (PubMed:27572839). In monocytes, activation leads to the release of CSF2, CF3, IL6, CXCL8 and CCL3 and down-regulates responses to bacterial lipopolysaccharide (LPS), possibly via down-regulation of TLR4 expression and reduced signaling via TLR4 (PubMed:22479404). In eosinophils, activation by ligand binding leads to the release of RNASE2, IL4 and leukotriene C4 (PubMed:12529506). Does not bind class I MHC antigens (PubMed:19230061).